60 Degrees Pharmaceuticals, Inc. (SXTP) AI Stock Analysis

• Market Cap: $3.39M
• Dividend Yield: N/A
• Average Volume (3M): 228.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.39
• Revenue Growth: 109.29%
• EPS Growth: -206.99%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -1.56
• Shares Outstanding: 1,472,891
• 10 Day Avg. Volume: 112,819
• 30 Day Avg. Volume: 228,744
• PEG Ratio: <0.01
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.55
• Enterprise Value/Market Cap: 0.05
• Enterprise Value/Revenue: 0.08
• Enterprise Value/Gross Profit: 0.63
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $7.00
• Price Target Upside: 204.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: $2.00 ▼(-13.04%Downside)

SXTP's overall stock score is primarily influenced by its weak financial performance and poor valuation metrics. The company's financial instability, highlighted by negative cash flow and profitability issues, heavily impacts the score. Technical analysis suggests a lack of strong market momentum, further contributing to a low stock score.

Positive Factors

Market Potential

The company survey indicates that Babesiosis prevalence could be significantly higher than CDC estimates, suggesting a larger potential market for Tafenoquine.

Regulatory Advantage

Arakoda was granted FDA Orphan Drug Designation for the treatment of babesiosis, which is a rare seasonal disease.

Sales Growth

Arakoda sales continue to grow, with net product revenues reaching $607,574 in FY24, a significant increase from $253,573 in FY23.

Negative Factors

Earnings Performance

Q1 earnings per share were below estimates due to higher than forecast SG&A expenses.

Evaluation Challenge

It is difficult to evaluate the company prior to data from the clinical babesiosis program.

Market Insight

There is little insight into the malaria market and the company's findings from its pilot program are awaited.

60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model

Company Description

60 Degrees Pharmaceuticals, Inc. (SXTP) is a pharmaceutical company specializing in the development and commercialization of treatments for tropical diseases. The company's core focus is on providing innovative solutions for the prevention and treatment of diseases such as malaria and dengue fever. By leveraging scientific research and strategic collaborations, 60 Degrees Pharmaceuticals seeks to enhance global health outcomes particularly in areas most affected by these conditions.

How the Company Makes Money

60 Degrees Pharmaceuticals, Inc. generates revenue through the development and sale of pharmaceutical products designed to treat and prevent tropical diseases. The company earns income from product sales, licensing agreements, and research and development collaborations. Key revenue streams include government contracts, partnerships with non-governmental organizations, and sales to international markets where tropical diseases are prevalent. Additionally, the company may receive funding and grants from global health initiatives and foundations that support the fight against infectious diseases.

60 Degrees Pharmaceuticals, Inc. Financial Statement Overview

Summary

The company is facing significant financial challenges, with declining revenues, persistent losses, and negative cash flow. While there have been some improvements in equity and debt levels, the overall financial health remains weak, warranting a low score.

Income Statement

The company has been experiencing declining revenues, with a significant drop in total revenue from 2020 to 2023. Gross profit margin has been negative in recent years, indicating cost management issues. Net profit margin has been consistently negative, reflecting ongoing unprofitability. Despite some revenue growth in 2024, profitability remains a major concern.

Balance Sheet

The debt-to-equity ratio improved significantly from previous years due to reduced total liabilities, but the company still has challenges with negative equity in past years. In 2024, equity became positive, which is a positive sign. The equity ratio indicates a relatively higher reliance on equity compared to previous years.

Cash Flow

The company has struggled with negative operating cash flow in recent years, indicating challenges with cash generation from core operations. Free cash flow has also been negative, reflecting ongoing investment and financing needs. Positive financing cash flows suggest reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	655.39K	607.57K	253.57K	223.21K	1.16M	2.18M
Gross Profit	262.79K	222.81K	-220.98K	-209.16K	309.60K	1.48M
EBITDA	-10.25M	-7.88M	-1.43M	-2.11M	-1.01M	-341.17K
Net Income	-10.25M	-7.95M	-3.77M	-6.18M	-4.25M	-3.03M
Balance Sheet
Total Assets	5.98M	5.76M	7.78M	1.30M	1.39M	2.61M
Cash, Cash Equivalents and Short-Term Investments	3.45M	3.39M	2.14M	264.87K	115.40K	191.70K
Total Debt	155.27K	155.89K	172.67K	22.42M	18.80M	19.14M
Total Liabilities	1.95M	1.87M	2.99M	25.45M	19.55M	20.68M
Stockholders Equity	4.11M	4.04M	4.87M	-23.58M	-17.58M	-17.50M
Cash Flow
Free Cash Flow	-6.28M	-5.83M	-4.66M	-1.07M	-684.50K	-238.28K
Operating Cash Flow	-6.11M	-5.65M	-4.54M	-1.01M	-649.11K	-167.30K
Investing Cash Flow	-176.78K	-1.89M	-115.89K	-60.13K	-35.39K	-70.98K
Financing Cash Flow	6.85M	7.05M	6.47M	1.22M	611.23K	277.36K

60 Degrees Pharmaceuticals, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 2.3 is below the 20-day moving average (MA) of 2.49, below the 50-day MA of 2.51, and below the 200-day MA of 3.95, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 46.73 is Neutral, neither overbought nor oversold. The STOCH value of 80.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.

60 Degrees Pharmaceuticals, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	17.09%	1.64%
SXTP	41 Neutral	$3.39M	―	-181.43%	―	109.29%	-206.99%
ADIL	32 Underperform	$5.29M	―	-217.01%	―	―	45.99%
DRMA	15 Underperform	$3.85M	―	-206.26%	―	―	75.68%